This excerpt taken from the GSK 20-F filed Feb 29, 2008.
Lamictal. The patent on lamotrigine is not due to expire until 2009a,c (USA). Litigation challenging the validity of this patent in the USA has been settled on terms allowing for generic entry of tablet forms in mid-2008. In Europe, the corresponding patent has expired and generic competition exists.
Levitrad. GSK has co-promotion rights under the US patent on vardenafil, which is not due to expire until 2018.
Lexiva/Telzir. GSK is the exclusive licensee under the patent on fosamprenavir, which is not due to expire until 2017 (USA) and 2019b (Europe).
Lovaza. The formulation of omega-3 acid ethyl esters is protected by a patent that expires in the USA in 2018.
Paxil/Seroxat. The patent on the commercial form of paroxetine has expired and generic competition exists on Paxil instant release (IR) forms in the USA, Europe and other markets. Litigation relating to patents protecting the product is ongoing in the USAe. Paxil CR is protected by a patent issued in June 2007 relating to a delayed and controlled release formulation of paroxetine hydrochloride. Litigation relating to this patent has been settled on terms allowing for generic entry on all strengths of Paxil CR no later than fourth quarter 2008e.
Requip. The patent on ropinirole expired in 2007a in the USA and is due to expire in November 2008b in Europe. A patent relating to the use of ropinirole in Parkinsons disease is not due to expire until May 2008 (USA) and 2011b (Europe). Litigation challenging the validity of the Parkinsons use patent in the USA has been dismissed by the court, and generic entry is not expected until after expiry of the patent in May 2008e.
Serevent. The patent on salmeterol xinafoate expires in August 2008 in the USA. In Europe, the patent has expired, except in France (December 2008b) and Italy (2009b).
Trizivir. The patent on the method of treatment using a combination of lamivudine, zidovudine and abacavir does not expire until 2016 (USA) and 2016 (Europe).
Tykerb/Tyverb. The Patent on lapatinib is not due to expire until 2020a in the USA and 2022b in Europe.
Valtrex. The patent on valaciclovir is not due to expire until 2009a (USA) and 2009b (Europe, except Greece and Spain (August 2008)). Litigation challenging the validity of the patent in the USA has been settled on terms allowing for generic entry in late 2009e.
Wellbutrin SR, Wellbutrin XL and Zyban. The patent on the active ingredient has expired. There is now generic competition for the sustained release (SR) instant release (IR) and 300mg dosage form of Wellbutrin XL in the USA. Litigation in the USA relating to formulation patents covering Wellbutrin XL has been settled on terms allowing generic entry for the 150mg form in 2008. In Europe, regulatory data exclusivity provides protection until 2009 in some markets.
Ziagen. The patent on abacavir is not due to expire until 2012a,c (USA) and 2014b (Europe).
Zofran. The patent on ondansetron has expired in the USA and Europe, (except Italy (November 2008b)). A patent on use in treating emesis has also expired. Generic competition exists in the USA, Europe and other markets.
Trademark protection may generally be extended for as long as the trademark is used by renewing it when necessary. GSKs trademarks on pharmaceutical products are important for maintaining the brand identity of the product upon expiration of the patent.
The Consumer Healthcare trademarks are particularly important, as the business is very brand oriented and many products do not have patent protection.